<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.2" xml:lang="ru" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="issn">2658-6533</journal-id><journal-title-group><journal-title>Research Results in Biomedicine</journal-title></journal-title-group><issn pub-type="epub">2658-6533</issn></journal-meta><article-meta><article-id pub-id-type="doi">10.18413/2313-8955-2016-2-4-13-18</article-id><article-id pub-id-type="publisher-id">864</article-id><article-categories><subj-group subj-group-type="heading"><subject>Medicine (miscellaneous)</subject></subj-group></article-categories><title-group><article-title>THE ROLE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE DEVELOPMENT OF POLYMORBIDITY PATHOLOGY</article-title><trans-title-group xml:lang="en"><trans-title>THE ROLE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE DEVELOPMENT OF POLYMORBIDITY PATHOLOGY</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Efremova</surname><given-names>Olga A.</given-names></name><name xml:lang="en"><surname>Efremova</surname><given-names>Olga A.</given-names></name></name-alternatives><email>efremova@bsu.edu.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Kamyshnikova</surname><given-names>Lyudmila A.</given-names></name><name xml:lang="en"><surname>Kamyshnikova</surname><given-names>Lyudmila A.</given-names></name></name-alternatives><email>kamyshnikova@bsu.edu.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Shelyakina</surname><given-names>Elena V.</given-names></name><name xml:lang="en"><surname>Shelyakina</surname><given-names>Elena V.</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Shkileva</surname><given-names>Irina Yu.</given-names></name><name xml:lang="en"><surname>Shkileva</surname><given-names>Irina Yu.</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Efimenko</surname><given-names>Evgeny V.</given-names></name><name xml:lang="en"><surname>Efimenko</surname><given-names>Evgeny V.</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Нodosh</surname><given-names>Eduard M.</given-names></name><name xml:lang="en"><surname>Нodosh</surname><given-names>Eduard M.</given-names></name></name-alternatives><email>gen_khodosh@mail.ru</email></contrib></contrib-group><pub-date pub-type="epub"><year>2016</year></pub-date><volume>2</volume><issue>4</issue><fpage>0</fpage><lpage>0</lpage><self-uri content-type="pdf" xlink:href="/media/medicine/2016/4/Медицина_и_фармация-13-18.pdf" /><abstract xml:lang="ru"><p>The article provides a description of chronic obstructive pulmonary disease (COPD), which is one of the leading causes of morbidity and mortality worldwide. COPD is characterized by partially irreversible airflow limitation in the airways and steadily progressive nature. The authors revealed the most common complication of the disease, which is mostly frequent in patients over 40 years. The growing multiplicity of diseases with age reflect primarily involution processes. There is emphasis on the fact that the defeat of the pulmonary system leads to changes not only in the cardiovascular system but also results in the damage of other.</p></abstract><trans-abstract xml:lang="en"><p>The article provides a description of chronic obstructive pulmonary disease (COPD), which is one of the leading causes of morbidity and mortality worldwide. COPD is characterized by partially irreversible airflow limitation in the airways and steadily progressive nature. The authors revealed the most common complication of the disease, which is mostly frequent in patients over 40 years. The growing multiplicity of diseases with age reflect primarily involution processes. There is emphasis on the fact that the defeat of the pulmonary system leads to changes not only in the cardiovascular system but also results in the damage of other.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>chronic obstructive pulmonary disease</kwd><kwd>cardiovascular system</kwd><kwd>pulmonary heart disease</kwd><kwd>coronary artery disease</kwd><kwd>arterial hypertension</kwd><kwd>atrial fibrillation</kwd><kwd>liver damage</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic obstructive pulmonary disease</kwd><kwd>cardiovascular system</kwd><kwd>pulmonary heart disease</kwd><kwd>coronary artery disease</kwd><kwd>arterial hypertension</kwd><kwd>atrial fibrillation</kwd><kwd>liver damage</kwd></kwd-group></article-meta></front><back><ref-list><title>Список литературы</title><ref id="B1"><mixed-citation>Akramova E.G. Characteristics of Cardiac Arrhythmias in Patients with Chronic Obstructive Pulmonary Disease. Clinical Medicine. 2013 2. Pp 105-107.</mixed-citation></ref><ref id="B2"><mixed-citation>Gurova A.Yu., Chaplyigin A.V., Svet T.E. Features of Rational Pharmacotherapy of Beta-blockers in Combination with Ischemic Heart Disease and Chronic Obstructive Pulmonary Disease. Lech. Doctor. 2012. 2. Pp. 2.</mixed-citation></ref><ref id="B3"><mixed-citation>Efimenko E.V. Efremova O.A., Khodosh E.M. Diagnostic Symptoms for a Probabilistic Risk Assessment of Exacerbations of Chronic Obstructive Pulmonary Disease. Belgorod State University Scientific Bulletin. Series: Medicine. Pharmacy. 2016. Vol. 33. 5 (226). Pp. 15-20.</mixed-citation></ref><ref id="B4"><mixed-citation>Zadionchenko V.S., Adasheva T.V., Shilova E.V. Clinical and Functional Features of Arterial Hypertension in Patients with Chronic Obstructive Pulmonary Disease. Russian Medical Journal. 2003. 11. Pp 535-538.</mixed-citation></ref><ref id="B5"><mixed-citation>Lazebnik L.B., Bordin D.S., Masharova A.A. Modern Understanding of Gastroesophageal Reflux Disease: from Genval to Montreal // Experimental and Clinical Gastroenterology. 2007. 5. Pp 410.</mixed-citation></ref><ref id="B6"><mixed-citation>Polymorbidity Problem with a Combination of Chronic Obstructive Pulmonary Disease and Certain Cardiovascular Diseases. Correia L.L. Lebedev T.Yu., Efremova O.A., Proshaev K.I. Litovchenko E.S. Belgorod State University Scientific Bulletin. Series: Medicine. Pharmacy. 2013. Vol. 21. №4 (147). Pp. 12-17.</mixed-citation></ref><ref id="B7"><mixed-citation>Sinopalnikov A.I. The New in the Pharmacotherapy of Chronic Obstructive Pulmonary Disease &amp;ndash; Prevention of Exacerbations of the Disease (in the roflumilast focus). Clinical Medicine. 2014. 2. Pp. 57-64.</mixed-citation></ref><ref id="B8"><mixed-citation>Difficulties in the Management of Patients with Chronic Heart Failure in Primary Care. Kamyshnikova L.A., Efremova O.A., Sviridova M.S., Osipova O.A., Correia L.L. Belgorod State University Scientific Bulletin. Series: Medicine. Pharmacy. 2013. Vol. 21. (147). Pp. 73-76.</mixed-citation></ref><ref id="B9"><mixed-citation>Statsenko M.E., Derevyanchenko M.V. Place of Beta-blockers in the Treatment of Cardiovascular Disease in Patients with Chronic Obstructive Pulmonary Disease. Journal Archive. 2012. 12. Pp. 7-16.</mixed-citation></ref><ref id="B10"><mixed-citation>Tatarskiy A.R., Babak S.L., Kiryuhin A.V. Chronic Obstructive Pulmonary Disease. Pulmonology. 2004. 4. Pp. 36-39.</mixed-citation></ref><ref id="B11"><mixed-citation>Khodosh E.M., Efremova O.A. Classification of COPD in the Aspect of Gold (2007, 2011-2014): from the stage to group membership. Belgorod State University Scientific Bulletin. Series: Medicine. Pharmacy. 2015. T. 31. 16 (213). Pp. 5-11.</mixed-citation></ref><ref id="B12"><mixed-citation>Chuchalin A.G., Tseymah I.Ja., Momot A.P., Mamayev A.N., Karbyishev I.A., Kostyuchenko G.I. Changes in Systemic Inflammatory and Hemostatic Responses in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease Associated with Chronic Heart Failure and Obesity. Pulmonology. 2014.6. Pp. 25-32.</mixed-citation></ref><ref id="B13"><mixed-citation>Shepelenko A.F., Mironov M.B., Sidorov Yu.O. Comprehensive Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease. Lech. Doctor. 2006. 8. Pp. 14-16.</mixed-citation></ref><ref id="B14"><mixed-citation>Shilov A.M., Tarasenko O.F., Osiya A.O. Features of Treatment of Coronary Heart Disease combined with Chronic Obstructive Pulmonary Disease. Lech. Doctor. 2009 7. Pp. 44-48.</mixed-citation></ref><ref id="B15"><mixed-citation>Bueno R., Sotomayor M., Perez-Guerrero C. et al. L-carnitine and propionyl-L-carnitine improve endothelial dysfunction in spontaneously hypertensive rats: different participation of NO and COX-products. Life Sci. 2005. 77. Pp. 2082-2097.</mixed-citation></ref><ref id="B16"><mixed-citation>Fabbri L.M., Luppi F., Beghe B. et al. Complex chronic comorbidities of COPD .Eur Respir J. 2008.31. Pp. 204-212.</mixed-citation></ref><ref id="B17"><mixed-citation>Sotomayor M., Mingorance C., Rodriguez-Rodriguez R. et al. L-carnitine and its propionate: improvement of endothelial function in SHR through superoxide dismutase-dependent mecha-nisms. Free Radic. Res. 2007.41.Pp. 884-891.</mixed-citation></ref><ref id="B18"><mixed-citation>Stallberg B., Selroos O., Vogelmeier C. et al. Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study. 2009.10. Pp. 11.</mixed-citation></ref></ref-list></back></article>